Atlas Trials

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

Clinical trial NCT06655662 · RECRUITING

Trial details

NCT number
NCT06655662
Sponsor
Shenzhen Hemogen
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Β-thalassemia
Start date
2024-06-12
Primary completion
2025-12-31
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.